News & Updates
Filter by Specialty:
Autoantibodies against type 1 interferons increase COVID-19 death risk
The presence of autoantibodies neutralizing type 1 interferons (IFN), such as IFN-α2 or IFN-ω, strongly increase the relative risk of death (RRD) and infection fatality rate (IFR) in unvaccinated patients with COVID-19, according to a recent study.
Autoantibodies against type 1 interferons increase COVID-19 death risk
14 Jun 2022Infection + vaccination = The best protection against COVID-19?
Individuals with a prior COVID-19 infection and who are fully vaccinated against COVID-19 appear to have the greatest immunity to the virus, according to the SIREN* study.
Infection + vaccination = The best protection against COVID-19?
13 Jun 2022Postpartum depression: Another outcome of the COVID-19 pandemic?
Several studies presented at ACOG 2022 have raised the question as to whether postpartum depression (PPD) is one of the mental health outcomes of the COVID-19 pandemic.
Postpartum depression: Another outcome of the COVID-19 pandemic?
08 Jun 2022Hepatitis E virus resistant to most alcohol-based disinfectants
Alcohols and alcohol-based disinfectants are not strong enough to eliminate the hepatitis E virus (HEV), except for one commercial ethanol-based product that has phosphoric acid, a study has shown. This finding may help develop measures to reduce transmission in clinical practice.
Hepatitis E virus resistant to most alcohol-based disinfectants
08 Jun 2022Microbiome-based therapy for recurrent CDI hits mark in patients with comorbidities
The investigational microbiota-based live biotherapeutic RBX2660 is safe and averts repeat episodes of Clostridioides difficile infection (CDI) across patient populations with comorbid conditions, as shown in a study presented at Digestive Disease Week (DDW) 2022.
Microbiome-based therapy for recurrent CDI hits mark in patients with comorbidities
07 Jun 2022H. pylori eradication suppresses long-term gastric cancer risk
Helicobacter pylori eradication treatment leads to large reductions in the risk of gastric cancer and lower rates of associated deaths over 10 years of follow-up, according to a recent meta-analysis.
H. pylori eradication suppresses long-term gastric cancer risk
07 Jun 2022Imatinib may reduce mortality in hospitalized COVID-19 patients
The tyrosine kinase inhibitor imatinib may reduce mortality in patients hospitalized with severe COVID-19, according to follow-up results of the CounterCOVID study presented at ATS 2022.